The Chinese NDRC fines two pharmaceutical companies for excessive pricing and refusal to deal (Zhejiang Second Pharma / Tianjin Handewei Pharmaceuticals)

Fels, Allan; Emch, Adrian; Ng, Wendy; Wang, Xiaoye

Article précédent The US Democrats publish "A Better Deal" policy statement with proposals to change antitrust/competition enforcement Article suivant The Spanish High Court rules that the constitutional principle of the individual nature of penalties precludes a parent company from being held to be the perpetrator of anti-competitive practices on the market in the motor fuels market solely because of its shareholding in the capital of its subsidiary (Repsol)

31 Jul 2017

The Chinese NDRC fines two pharmaceutical companies for excessive pricing and refusal to deal (Zhejiang Second Pharma / Tianjin Handewei Pharmaceuticals)

KEYWORDS

Reference

Chinese NDRC, Zhejiang Second Pharma / Tianjin Handewei Pharmaceuticals, Press Release, 31 July 2017 (Chinese)

On 31 July 2017, the NDRC publicly announced its decision to sanction Zhejiang Second Pharma (an affiliate of a

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

Version PDF

Auteurs

Allan Fels
University of Melbourne

Australie 103 contributions 29052 visites
Adrian Emch
Hogan Lovells (Beijing)

Chine 81 contributions 19799 visites
Wendy Ng
University of Melbourne

Australie 68 contributions 15885 visites
Xiaoye Wang
China Competition Bulletin (Beijing)

Chine 101 contributions 26009 visites

Citation

Allan Fels, Adrian Emch, Wendy Ng, Xiaoye Wang, The Chinese NDRC fines two pharmaceutical companies for excessive pricing and refusal to deal (Zhejiang Second Pharma / Tianjin Handewei Pharmaceuticals), 31 juillet 2017, e-Competitions July 2017, Art. N° 88631

Visites 210

Tous les numéros

Latest News issue
Tous les News issues
Latest Special issue
Tous les Special issues